LKB1-AMPK activators (NovaTarg)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameLKB1-AMPK activators (NovaTarg)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase STK11 stimulantsAMP-activated protein kinases activators
TargetsSerine/threonine-protein kinase STK11AMP-activated protein kinases
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNovaTarg Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovaTarg Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A